Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

Bibliography

• Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64:1215-26
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56
   PubMed Web of Science ®Google Scholar
• Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198-204
   PubMed Web of Science ®Google Scholar
• Laabi Y, Gras M-P, Brouet J-C, et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 1994;22:1147-54
   PubMed Web of Science ®Google Scholar
• von Bülow G-U, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278:138-41
   PubMed Web of Science ®Google Scholar
• Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-11
   PubMed Web of Science ®Google Scholar
• Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001;11:1547-52
   PubMed Web of Science ®Google Scholar
• Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 2012;188:497-503
   PubMed Web of Science ®Google Scholar
• Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000;192:129-35
   PubMed Web of Science ®Google Scholar
• Do RKG, Hatada E, Lee H, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-64
   PubMed Web of Science ®Google Scholar
• Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-65
   PubMed Web of Science ®Google Scholar
• Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002;32:2004-10
   PubMed Web of Science ®Google Scholar
• Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9
   PubMed Web of Science ®Google Scholar
• Yu G, Boone T, Delaney J, et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000;1:252-6
   PubMed Web of Science ®Google Scholar
• Yan M, Marsters SA, Grewal IS, et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000;1:37-41
   PubMed Web of Science ®Google Scholar
• Xia X-Z, Treanor J, Senaldi G, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000;192:137-43
   PubMed Web of Science ®Google Scholar
• Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302
   PubMed Web of Science ®Google Scholar
• Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-14
   PubMed Web of Science ®Google Scholar
• Goenka R, Matthews AH, Zhang B, et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med 2014;211:45-56
   PubMed Web of Science ®Google Scholar
• Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008;180:3655-9
   PubMed Web of Science ®Google Scholar
• Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008;105:15517-22
   PubMed Web of Science ®Google Scholar
• Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-53
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-98
   PubMed Web of Science ®Google Scholar
• Aït-Azzouzene D, Gavin AL, Skog P, et al. Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of Igκ-reactive macroself antigen. Eur J Immunol 2006;36:985-96
   PubMedGoogle Scholar
• Ota M, Duong BH, Torkamani A, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010;185:4128-36
   PubMed Web of Science ®Google Scholar
• Nikbakht N, Migone T-S, Ward CP, Manser T. Cellular competition independent of BAFF/B lymphocyte stimulator results in low frequency of an autoreactive clonotype in mature polyclonal B cell compartments. J Immunol 2011;187:37-46
   PubMedGoogle Scholar
• Yang M, Sun L, Wang S, et al. Cutting edge: novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 2010;184:3321-5
   PubMed Web of Science ®Google Scholar
• Shu H-B, Hu W-H, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999;65:680-3
   PubMed Web of Science ®Google Scholar
• Tribouley C, Wallroth M, Chan V, et al. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 1999;380:1443-7
   PubMed Web of Science ®Google Scholar
• Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003;197:297-302
   PubMed Web of Science ®Google Scholar
• Gorelik L, Gilbride K, Dobles M, et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003;198:937-45
   PubMed Web of Science ®Google Scholar
• Vincent FB, Saulep-Easton D, Figgett WA, et al. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 2013;24:203-15
   PubMed Web of Science ®Google Scholar
• Kim H-A, Jeon S-H, Seo G-Y, et al. TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways. J Leukocyte Biol 2008;83:1431-9
   PubMedGoogle Scholar
• Panchanathan R, Choubey D. Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol 2013;53:15-23
   PubMed Web of Science ®Google Scholar
• Claudio E, Brown K, Park S, et al. BAFF-induced NEMO-independent processing of NK-kappaB2 in maturing B cells. Nat Immunol 2002;3:958-65
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002;17:515-24
   PubMed Web of Science ®Google Scholar
• Hatada EN, Do RKG, Orlofsky A, et al. NF-kappaB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappaB2 p100 to p52 in quiescent mature B cells. J Immunol 2003;171:761-8
   PubMed Web of Science ®Google Scholar
• Enzler T, Bonizzi G, Silverman GJ, et al. Alternative and classical NF-kappaB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006;25:403-15
   PubMed Web of Science ®Google Scholar
• Gardam S, Sierro F, Basten A, et al. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008;28:391-401
   PubMed Web of Science ®Google Scholar
• Xie P, Stunz LL, Larison KD, et al. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity 2007;27:253-67
   PubMed Web of Science ®Google Scholar
• Bishop GA. The many faces of TRAF molecules in immune regulation. J Immunol 2013;191:3483-5
   PubMedGoogle Scholar
• Huard B, Schneider P, Mauri D, et al. T cell costimulation by the TNF ligand BAFF. J Immunol 2001;167:6225-31
   PubMed Web of Science ®Google Scholar
• Ng LG, Sutherland APR, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-17
   PubMed Web of Science ®Google Scholar
• Sutherland APR, Ng LG, Fletcher CA, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005;174:5537-44
   PubMed Web of Science ®Google Scholar
• Zhou X, Xia Z, Lan Q, et al. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One 2011;6:e23629
   PubMedGoogle Scholar
• Walters S, Webster KE, Sutherland A, et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009;182:793-801
   PubMedGoogle Scholar
• Kanakaraj P, Migone T-S, Nardelli B, et al. BLyS binds to B cells with high affinity and induces activation of the transcription factors NF-kappaB and ELF-1. Cytokine 2001;13:25-31
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu L, Opalka N, et al. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002;108:383-94
   PubMed Web of Science ®Google Scholar
• Kim HM, Yu KS, Lee ME, et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol 2003;10:342-8
   PubMedGoogle Scholar
• Liu Y, Hong X, Kappler J, et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature 2003;423:49-56
   PubMed Web of Science ®Google Scholar
• Karpusas M, Cachero TG, Qian F, et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 2002;315:1145-54
   PubMed Web of Science ®Google Scholar
• Oren DA, Li Y, Volovik Y, et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002;9:288-92
   PubMedGoogle Scholar
• Zhukovsky EA, Lee J-O, Villegas M, et al. Is TALL-1 a trimer of a virus-like cluster? Nature 2004;427:413-14
   PubMedGoogle Scholar
• Bossen C, Cachero TG, Tardivel A, et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008;111:1004-12
   PubMed Web of Science ®Google Scholar
• Bossen C, Tardivel A, Willen L, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody response. Eur J Immunol 2011;41:787-97
   PubMed Web of Science ®Google Scholar
• Nys J, Smulski CR, Tardivel A, et al. No evidence that soluble TACI induces signalling via membrane-expressed BAFF and APRIL in myeloid cells. PLoS One 2013;8:e61350
   PubMedGoogle Scholar
• Gavin AL, Aït-Azzouzene D, Ware CF, et al. ΔBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003;278:38220-8
   PubMedGoogle Scholar
• Gavin AL, Duong B, Skog P, et al. ΔBAFF, a splice isoform of BAFF, opposes full length BAFF activity in vivo in transgenic mouse models. J Immunol 2005;175:319-28
   PubMedGoogle Scholar
• Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710
   PubMed Web of Science ®Google Scholar
• Khare SD, Sarosi I, Xia X-Z, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97:3370-5
   PubMed Web of Science ®Google Scholar
• Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9
   PubMed Web of Science ®Google Scholar
• Stohl W, Jacob N, Guo S, Morel L. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum 2010;62:2432-42
   PubMedGoogle Scholar
• Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007;204:1959-71
   PubMed Web of Science ®Google Scholar
• Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005;52:2080-91
   PubMed Web of Science ®Google Scholar
• Jacob CO, Pricop L, Putterman C, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF. J Immunol 2006;177:2671-80
   PubMed Web of Science ®Google Scholar
• Jacob N, Guo S, Mathian A, et al. B cell and BAFF dependence of IFN-alpha-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 2011;186:4984-93
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Wang X, Huang W, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004;173:3524-34
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724-34
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10
   PubMed Web of Science ®Google Scholar
• Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-19
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan S-M, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86
   PubMed Web of Science ®Google Scholar
• Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9
   PubMed Web of Science ®Google Scholar
• Collins CE, Gavin AL, Migone T-S, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006;8:R6
   PubMed Web of Science ®Google Scholar
• Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006;15:570-6
   PubMed Web of Science ®Google Scholar
• Ju S, Zhang D, Wang Y, et al. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006;39:1131-7
   PubMed Web of Science ®Google Scholar
• McCarthy EM, Lee RZ, Ni Gabhann J, et al. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology 2013;52:1279-84
   PubMed Web of Science ®Google Scholar
• Price JV, Haddon DJ, Kemmer D, et al. Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus. J Clin Invest 2013;123:5135-45
   PubMed Web of Science ®Google Scholar
• Hahne M, Kataoka T, Schröter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90
   PubMed Web of Science ®Google Scholar
• Kelly K, Manos E, Jensen G, et al. APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 2000;60:1021-7
   PubMed Web of Science ®Google Scholar
• Marsters SA, Yan M, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the receptor homologues BCMA and TACI. Curr Biol 2000;10:785-8
   PubMed Web of Science ®Google Scholar
• Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000;275:35478-85
   PubMed Web of Science ®Google Scholar
• Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000;192:1677-83
   PubMed Web of Science ®Google Scholar
• López-Fraga M, Fernández R, Albar JP, et al. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001;2:945-51
   PubMed Web of Science ®Google Scholar
• Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005;201:35-9
   PubMed Web of Science ®Google Scholar
• Sakurai D, Hase H, Kanno Y, et al. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007;109:2961-7
   PubMed Web of Science ®Google Scholar
• He B, Xu W, Santini PA, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A2 class switching by inducing eipthelial-cell secretion of the cytokine APRIL. Cell 2007;26:812-26
   Google Scholar
• Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111:2755-64
   PubMed Web of Science ®Google Scholar
• Hendriks J, Planelles L, de Jong-Odding J, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005;12:637-48
   PubMed Web of Science ®Google Scholar
• Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375-83
   PubMed Web of Science ®Google Scholar
• Huard B, McKee T, Bosshard C, et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008;118:2887-95
   PubMed Web of Science ®Google Scholar
• Pradet-Balade B, Medema JP, López-Fraga M, et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002;21:5711-20
   PubMed Web of Science ®Google Scholar
• Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21
   PubMed Web of Science ®Google Scholar
• Dillon SR, Harder B, Lewis KB, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010;12:R48
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004;24:997-1006
   PubMed Web of Science ®Google Scholar
• Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004;101:3903-8
   PubMed Web of Science ®Google Scholar
• Stein JV, López-Fraga M, Elustondo FA, et al. APRIL modulates B and T cell immunity. J Clin Invest 2002;109:1587-98
   PubMed Web of Science ®Google Scholar
• Jacob CO, Guo S, Jacob N, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012;64:1610-19
   PubMed Web of Science ®Google Scholar
• Huard B, Tran NL, Benkhoucha M, et al. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 2012;7:e31837
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Masumoto K, et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology 2003;42:980-5
   PubMed Web of Science ®Google Scholar
• Lee YH, Ota F, Kim-Howard X, et al. APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology 2007;46:1274-6
   PubMed Web of Science ®Google Scholar
• Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 2013;41:25-33
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-7
   PubMed Web of Science ®Google Scholar
• Hegazy M, Darwish H, Darweesh H, et al. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. Clin Immunol 2010;135:118-24
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan S-M, et al. Inverse association between circulating APRIL levels and serologic and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096-103
   PubMed Web of Science ®Google Scholar
• Morel J, Roubille C, Planelles L, et al. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus. Ann Rheum Dis 2009;68:997-1002
   PubMed Web of Science ®Google Scholar
• Zhang L, Zheng S, Wu H, et al. Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J Neurosci 2009;29:6348-52
   PubMed Web of Science ®Google Scholar
• Mihalcik SA, Huddleston PM III, Wu X, Jelinek DF. The structure of the TNFRSF13C promoter enables differential expression of BAFF-R during B cell ontogeny and terminal differentiation. J Immunol 2010;185:1045-54
   PubMed Web of Science ®Google Scholar
• Pieper K, Rizzi M, Speletas M, et al. A common single nucleotide polymorphism impairs B-cell activating factor receptor's multimerization, contributing to common variable immunodeficiency. J Allergy Clin Immunol 2014; Online
   Google Scholar
• Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103:689-94
   PubMed Web of Science ®Google Scholar
• Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-86
   PubMed Web of Science ®Google Scholar
• Underhill GH, George D, Bremer EG, Kansas GS. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 2003;101:4013-21
   PubMed Web of Science ®Google Scholar
• Tarte K, Zhan F, De Vos J, et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003;102:592-600
   PubMed Web of Science ®Google Scholar
• Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286-97
   PubMed Web of Science ®Google Scholar
• Yang M, Hase H, Legarda-Addison D, et al. BCMA, the receptor for APRIL and BAFF, induces antigen presentation in B cells. J Immunol 2005;175:2814-24
   PubMed Web of Science ®Google Scholar
• Stadanlick JE, Kaileh M, Karnell FG, et al. Tonic B cell antigen receptor signals supply an NK-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008;9:1379-87
   PubMed Web of Science ®Google Scholar
• Deng S, Yuan T, Cheng X, et al. B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells. Mol Biol Rep 2010;37:3747-55
   PubMedGoogle Scholar
• Peperzak V, Vikström I, Walker J, et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol 2013;14:290-7
   PubMedGoogle Scholar
• Smith SH, Cancro MP. Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J Immunol 2003;170:5820-3
   PubMed Web of Science ®Google Scholar
• Treml LS, Carlesso G, Hoek KL, et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007;178:7531-9
   PubMed Web of Science ®Google Scholar
• Bischof D, Elsawa SF, Mantchev G, et al. Selective activation of TACI by syndecan-2. Blood 2006;107:3235-42
   PubMedGoogle Scholar
• O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-7
   PubMed Web of Science ®Google Scholar
• Xu S, Lam D-P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001;21:4067-74
   PubMed Web of Science ®Google Scholar
• Ou X, Xu S, Lam K-P. Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cells survival. Proc Natl Acad Sci USA 2012;109:15401-6
   PubMed Web of Science ®Google Scholar
• von Bülow G-U, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001;14:573-82
   PubMed Web of Science ®Google Scholar
• Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001;2:638-43
   PubMed Web of Science ®Google Scholar
• Seshasayee D, Valdez P, Yan M, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-88
   PubMed Web of Science ®Google Scholar
• Sakurai D, Kanno Y, Hase H, et al. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol 2007;37:110-18
   PubMed Web of Science ®Google Scholar
• Figgett WA, Fairfax K, Vincent FB, et al. The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death. Immunity 2013;39:573-83
   PubMedGoogle Scholar
• Romberg N, Chamberlain N, Saadoun D, et al. CVID-asociated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest 2013;123:4283-93
   PubMed Web of Science ®Google Scholar
• He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010;11:836-45
   PubMed Web of Science ®Google Scholar
• Salzer U, Chapel HM, Webster ADB, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37:820-8
   PubMed Web of Science ®Google Scholar
• Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-34
   PubMed Web of Science ®Google Scholar
• Martínez-Pomar N, Detková D, Arostegui JI, et al. Role of TNFRSF13B variants in patients with common variable immunodeficiency. Blood 2009;114:2846-8
   PubMedGoogle Scholar
• Martinez-Gallo M, Radigan L, Almejún MB, et al. TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes. J Allergy Clin Immunol 2013;131:468-76
   PubMedGoogle Scholar
• Mantchev GT, Cortesao CS, Rebrovich M, et al. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J Immunol 2007;179:2282-8
   PubMedGoogle Scholar
• Kanswal S, Katsenelson N, Selvapandiyan A, et al. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J Immunol 2008;181:976-90
   PubMedGoogle Scholar
• Tsuji S, Cortesao C, Bram RJ, et al. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood 2011;118:5832-9
   PubMed Web of Science ®Google Scholar
• Wolf AI, Mozdzanowska K, Quinn WJ III, et al. Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J Clin Invest 2011;121:3954-64
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Casola S, Kutok JL, et al. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004;173:2245-52
   PubMed Web of Science ®Google Scholar
• Shulga-Morskaya S, Dobles M, Walsh ME, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004;173:2331-41
   PubMed Web of Science ®Google Scholar
• Losi CG, Silini A, Fiorini C, et al. Mutational analysis of human BAFF receptor TNFRSF13C (BAFF-R) in patients with common variable immunodeficiency. J Clin Immunol 2005;25:496-502
   PubMed Web of Science ®Google Scholar
• Warnatz K, Salzer U, Rizzi M, et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci USA 2009;106:13945-50
   PubMed Web of Science ®Google Scholar
• Harless SM, Lentz VM, Sah AP, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001;11:1986-9
   PubMed Web of Science ®Google Scholar
• Jacob CO, Yu N, Guo S, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum 2013;65:1043-54
   PubMed Web of Science ®Google Scholar
• Jiang C, Loo WM, Greenley EJ, et al. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol 2011;186:6136-47
   PubMed Web of Science ®Google Scholar
• Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 2013;22:144-54
   PubMed Web of Science ®Google Scholar
• Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37
   PubMed Web of Science ®Google Scholar
• Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012;39:1632-40
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41:300-9
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
   PubMed Web of Science ®Google Scholar
• Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8
   PubMed Web of Science ®Google Scholar
• Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9
   PubMed Web of Science ®Google Scholar
• Ke X, Patel J, Kan H, et al. Characteristics and medication use patterns among belimumab users in a commercially insured population with systemic lupus erythematosus. Arthritis Rheum 2013;65:S457
   PubMedGoogle Scholar
• Askanase A, Reddy A, Buyon JP, et al. Favorable clinical response to belimumab to three months. Arthritis Rheum 2013;65:S668
   Google Scholar
• Yazdany J, Erkan D, Sanchez-Guerrero J, et al. Post-marketing experience with belimumab in U.S. lupus centers: data from the Lupus Clinical Trials Consortium, Inc. (LCTC) national patient registry. Arthritis Rheum 2013;65:S681
   PubMed Web of Science ®Google Scholar
• Collins CE, Dall'Era M, Oglesby A, et al. 12-month outcomes associated with belimumab in patients with systemic lupus erythematosus in clinical practice settings: the observe study. Arthritis Rheum 2013;65:S738-9
   Google Scholar
• Ramos-Casals M, Díaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 2009;61:1281-2
   PubMed Web of Science ®Google Scholar
• Harvey PR, Gordon C. B-cell targeted therapies in systemic lupus erythematosus. BioDrugs 2013;27:85-95
   PubMed Web of Science ®Google Scholar
• Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol 2006;121:1-12
   PubMed Web of Science ®Google Scholar
• Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 2007;179:3351-61
   PubMed Web of Science ®Google Scholar
• Haas KM, Watanabe R, Matsushita T, et al. Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 2010;184:4789-800
   PubMedGoogle Scholar
• Watanabe R, Ishiura N, Nakashima H, et al. Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010;184:4801-9
   PubMed Web of Science ®Google Scholar
• Blair PA, Noreña LY, Flores-Borja F, et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals by are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32:129-40
   PubMed Web of Science ®Google Scholar
• Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117:530-41
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264-83
   PubMed Web of Science ®Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14:R33
   PubMed Web of Science ®Google Scholar
• Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26
   PubMed Web of Science ®Google Scholar
• Cambridge G, Isenberg DA, Edwards JCW, et al. B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-16
   PubMed Web of Science ®Google Scholar
• Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimbürger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167
   PubMed Web of Science ®Google Scholar
• Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65:2672-9
   PubMed Web of Science ®Google Scholar
• Kawasaki A, Tsuchiya N, Fukazawa T, et al. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002;3:424-9
   PubMed Web of Science ®Google Scholar
• Eilertsen GO, Van Ghelue M, Strand H, Nossent JC. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology 2011;50:2197-205
   PubMed Web of Science ®Google Scholar